Investor Diligence and Decision Support
We support VC/CVC teams, Private Equity, Hedge Funds, and other investors with decision-grade intelligence in BioPharma, HealthTech, and AI-enabled healthcare. From fast diligence to ongoing monitoring, we help you validate assumptions, surface risks early, and act with confidence.
From identifying emerging trends and hidden risks to supporting diligence and portfolio decisions, we deliver concise, actionable recommendations that create an edge.
Our work commonly includes:
- Landscape + diligence (science, commercial, competitive dynamics)
- Company/asset profile (TAM, segmentation, growth drivers, value proposition)
- Opportunity/risk assessment (red flags, catalysts, scenarios, mitigations)
- Custom research aligned to your thesis and timelines (deal-specific questions, thesis validation, monitoring)
- Primary intelligence (targeted KOL and stakeholder interviews to resolve the specific uncertainties in your thesis)
Typical engagement modes:
- Diligence Sprint (5–10 business days)
- Monthly monitoring and brief updates
- Decision workshops and AI-powered wargaming (via LucidWargames) to stress-test theses and quantify scenario risk
Don’t forget to check out our Lucid Diligence Briefs, delivering 60-second theses, questions to ask, red flags and catalysts to watch, linked to trending news.
Want to move faster on your next decision? Contact: info@lqventures.com
January 3, 2026
Lucid Diligence Brief: Neuralink’s 2026 high-volume BCI plan
January 2, 2026
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
January 2, 2026
Public Health 2025 Review: Prevention Under Pressure and Signals Too Loud to Ignore
January 1, 2026
Cardiovascular 2025 Review: From late rescue to earlier, smarter intervention
January 1, 2026
Rare Disease 2025 Review: From Orphan Innovation to a System-Level Stress Test
December 31, 2025
Immunology 2025 Review: From Mechanism Proliferation to Platform Discipline
December 30, 2025
Endocrinology 2025 Review: Outcomes, Access, and Earlier Intervention
December 30, 2025
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
December 29, 2025